Between the doc and pharmacy, patients get online, says survey

Share this article:

Just 35% of the individuals surveyed by About.com in June said they would fill a prescription on doctor's orders after a diagnosis, without first doing research online.

Forty-seven percent said they would use a search engine to find more information about their specific condition, and a combined 36% said they would either go to a specific health website for more condition-related information (20%), or use a search engine to compare different treatment options (16%), according to the survey.

When asked what kinds of advertising grabs their attention, 29% of the surveyed respondents chose “information about a certain condition (sign, symptom, etc.),” with 28% pointing to information about medication side effects and safety, as an attention-grabber. Information about how to cope with a condition (20%) and free trial information (18%) registered slightly lower.

A majority of respondents to the survey said that after seeing an ad, they either spoke with their doctor (38%) or researched the drug in more detail online (36%). Less than 20% of the respondents spoke to friends or family for recommendations about the drug, visited the pharmaceutical company's website, or asked their doctor for a sample or script.

Erica McDonald, a spokesperson for About.com Health, said the survey looked specifically at healthcare ads online, as opposed to ads appearing in other media.

About.com's Health Site Intercept Study surveyed opt-in participants over three days in early June 2009, with a final participation number of 1,870. Respondents visiting three of About.com's channels – parenting, health and food – were invited via pop-up to participate in the survey.


Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.